Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial. (linkinghub.elsevier.com)

Authors: Lu S … Su W Journal: The Lancet Published: 2026-01-24 DOI: https://doi.org/10.1016/S0140-6736(25)01811-2